

Stockholm, 2018-12-11

PRESS RELEASE

One of the five largest pharmaceutical companies orders Uni-Qleaver® PEGs

QuiaPEG Pharmaceuticals Holding AB (publ) today announces that one of the five largest global pharmaceutical companies will place an initial order for activated PEGs (reagents) based on the Uni-Qleaver® platform.

After reporting the latest positive pre-clinical trials results, QuiaPEG will now deliver tailored reagents to a global pharmaceutical company, which will use the reagent in pre-clinical trials. If the tests are successful, this may result in larger orders and a commercial license agreement going forward. The global pharmaceutical company's identity and financial commitments is, for the moment, held confidential.

"It's important to get a foot in through the door of one the largest pharmaceutical companies, which has now placed an order for reagents, even though the amount for this order is limited. The order confirms the potential of Uni-Qleaver® and the business opportunities it may create in the future. Hopefully, this is the beginning of long-term and profitable development cooperation with one of the biggest pharmaceutical companies," says Marcus Bosson, CEO.

For further information, please contact:

Marcus Bosson

CEO

Tel: +46 (0) 70 693 12 53 e-mail: marcus.bosson@quiapeg.com www.quiapeg.com

This information is such that QuiaPEG Pharmaceuticals Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided, through the above contact person, for publication on December 11th, 2018.

About QuiaPEG Pharmaceuticals Holding AB (publ)

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, such as biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows a chosen release time for the drug through a controllable chemical coupling unit. QuiaPEG is listed on the Spotlight Stock Market in Stockholm.